SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.

Jonathan Tammela, Achim A. Jungbluth, Feng Qian, Darren Santiago, Matthew J. Scanlan, Bernadette Keitz, Deborah Driscoll, Kerry Rodabaugh, Shashikant Lele, Lloyd J. Old, Kunle Odunsi

Research output: Contribution to journalArticle

Abstract

SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15%) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines were negative for SCP-1 expression, as were a panel of other normal tissues. None of the patients whose tumors were determined to be SCP-1 positive by RT-PCR expressed the antigen by IHC or demonstrated a humoral immune response by ELISA. Tumors that expressed SCP-1 mRNA tended to have a higher grade than those that did not (P = 0.03). There was a significant decrease in survival time (P = 0.004) for patients with SCP-1 mRNA-positive tumors compared to those with SCP-1 mRNA-negative tumors [median 25 mo, 95% confidence interval (CI) 0-56 mo; and median 97 mo, CI 32-162 mo, respectively]. The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted.

Original languageEnglish (US)
Pages (from-to)10
Number of pages1
JournalCancer immunity : a journal of the Academy of Cancer Immunology
Volume4
StatePublished - 2004
Externally publishedYes

Fingerprint

Testicular Neoplasms
Immunotherapy
Antigens
Neoplasms
Messenger RNA
Polymerase Chain Reaction
Ovarian epithelial cancer
SCP 1
Epithelial Cells
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Confidence Intervals
Active Immunotherapy
Cell Line
Survival
Neoplasm Antigens
Humoral Immunity
Paraffin
RNA

Cite this

SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. / Tammela, Jonathan; Jungbluth, Achim A.; Qian, Feng; Santiago, Darren; Scanlan, Matthew J.; Keitz, Bernadette; Driscoll, Deborah; Rodabaugh, Kerry; Lele, Shashikant; Old, Lloyd J.; Odunsi, Kunle.

In: Cancer immunity : a journal of the Academy of Cancer Immunology, Vol. 4, 2004, p. 10.

Research output: Contribution to journalArticle

Tammela, J, Jungbluth, AA, Qian, F, Santiago, D, Scanlan, MJ, Keitz, B, Driscoll, D, Rodabaugh, K, Lele, S, Old, LJ & Odunsi, K 2004, 'SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.', Cancer immunity : a journal of the Academy of Cancer Immunology, vol. 4, pp. 10.
Tammela, Jonathan ; Jungbluth, Achim A. ; Qian, Feng ; Santiago, Darren ; Scanlan, Matthew J. ; Keitz, Bernadette ; Driscoll, Deborah ; Rodabaugh, Kerry ; Lele, Shashikant ; Old, Lloyd J. ; Odunsi, Kunle. / SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. In: Cancer immunity : a journal of the Academy of Cancer Immunology. 2004 ; Vol. 4. pp. 10.
@article{c5401d8561b448fbb213fabf93da6759,
title = "SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.",
abstract = "SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15{\%}) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines were negative for SCP-1 expression, as were a panel of other normal tissues. None of the patients whose tumors were determined to be SCP-1 positive by RT-PCR expressed the antigen by IHC or demonstrated a humoral immune response by ELISA. Tumors that expressed SCP-1 mRNA tended to have a higher grade than those that did not (P = 0.03). There was a significant decrease in survival time (P = 0.004) for patients with SCP-1 mRNA-positive tumors compared to those with SCP-1 mRNA-negative tumors [median 25 mo, 95{\%} confidence interval (CI) 0-56 mo; and median 97 mo, CI 32-162 mo, respectively]. The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted.",
author = "Jonathan Tammela and Jungbluth, {Achim A.} and Feng Qian and Darren Santiago and Scanlan, {Matthew J.} and Bernadette Keitz and Deborah Driscoll and Kerry Rodabaugh and Shashikant Lele and Old, {Lloyd J.} and Kunle Odunsi",
year = "2004",
language = "English (US)",
volume = "4",
pages = "10",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.

AU - Tammela, Jonathan

AU - Jungbluth, Achim A.

AU - Qian, Feng

AU - Santiago, Darren

AU - Scanlan, Matthew J.

AU - Keitz, Bernadette

AU - Driscoll, Deborah

AU - Rodabaugh, Kerry

AU - Lele, Shashikant

AU - Old, Lloyd J.

AU - Odunsi, Kunle

PY - 2004

Y1 - 2004

N2 - SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15%) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines were negative for SCP-1 expression, as were a panel of other normal tissues. None of the patients whose tumors were determined to be SCP-1 positive by RT-PCR expressed the antigen by IHC or demonstrated a humoral immune response by ELISA. Tumors that expressed SCP-1 mRNA tended to have a higher grade than those that did not (P = 0.03). There was a significant decrease in survival time (P = 0.004) for patients with SCP-1 mRNA-positive tumors compared to those with SCP-1 mRNA-negative tumors [median 25 mo, 95% confidence interval (CI) 0-56 mo; and median 97 mo, CI 32-162 mo, respectively]. The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted.

AB - SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15%) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines were negative for SCP-1 expression, as were a panel of other normal tissues. None of the patients whose tumors were determined to be SCP-1 positive by RT-PCR expressed the antigen by IHC or demonstrated a humoral immune response by ELISA. Tumors that expressed SCP-1 mRNA tended to have a higher grade than those that did not (P = 0.03). There was a significant decrease in survival time (P = 0.004) for patients with SCP-1 mRNA-positive tumors compared to those with SCP-1 mRNA-negative tumors [median 25 mo, 95% confidence interval (CI) 0-56 mo; and median 97 mo, CI 32-162 mo, respectively]. The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted.

UR - http://www.scopus.com/inward/record.url?scp=16644365140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644365140&partnerID=8YFLogxK

M3 - Article

C2 - 15487888

VL - 4

SP - 10

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

ER -